Theresa Kehoe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Theresa Kehoe has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Ann Punnoose
Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
1 shared publication - Donna R. Rivera
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD
1 shared publication - Eberhard Blind
European Medicines Agency, London, UK
1 shared publication Heidi Janssen
European Medicines Agency, London, E14 5EU, UK
1 shared publicationJie Li
Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA
1 shared publication- John Concato
Department of Medicine Yale University School of Medicine New Haven Connecticut USA
1 shared publication
Latest Publications
- 27 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (3) , 545-547
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
Advances in the availability and analysis of real‐world data (RWD) have enabled the generation of robust real‐world evidence (RWE) to support regulatory decision making by the US Food and Drug Administration. Realizing the full potential of RWE in a regulatory environment requires cross‐discipline expertise and collaboration to increase confidence in RWE‐based approaches. The FDA's Advancing RWE Program was established to address this need by providing a new option for regulatory interactions on RWE‐based approaches.
- 27 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (3) , 545-547
US Food and Drug Administration's Advancing Real‐World Evidence Program: Initial Experience
Advances in the availability and analysis of real‐world data (RWD) have enabled the generation of robust real‐world evidence (RWE) to support regulatory decision making by the US Food and Drug Administration. Realizing the full potential of RWE in a regulatory environment requires cross‐discipline expertise and collaboration to increase confidence in RWE‐based approaches. The FDA's Advancing RWE Program was established to address this need by providing a new option for regulatory interactions on RWE‐based approaches.
- 18 October 2018
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (6) , 1208-1212
Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective
Regulation of medicines involves complex scientific and public health policies which are reflected in the regulatory approaches used by the European Medicines Agency and the United States Food and Drug Administration for the approval of products developed for metabolic bone diseases. For osteoporosis therapies, utilized by many patients, approaches and existing guidance for product development of both Agencies are similar; confirmatory studies for the approval of osteoporosis products can rely on well‐defined efficacy outcome parameters. Therapeutics for rare bone diseases, a rapidly expanding area, often require an individualized regulatory approach. This review outlines key aspects of these regulatory approaches applied by the two Agencies for products for metabolic bone diseases.
- 18 October 2018
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 85 (6) , 1208-1212
Regulatory aspects of the development of drugs for metabolic bone diseases – FDA and EMA perspective
Regulation of medicines involves complex scientific and public health policies which are reflected in the regulatory approaches used by the European Medicines Agency and the United States Food and Drug Administration for the approval of products developed for metabolic bone diseases. For osteoporosis therapies, utilized by many patients, approaches and existing guidance for product development of both Agencies are similar; confirmatory studies for the approval of osteoporosis products can rely on well‐defined efficacy outcome parameters. Therapeutics for rare bone diseases, a rapidly expanding area, often require an individualized regulatory approach. This review outlines key aspects of these regulatory approaches applied by the two Agencies for products for metabolic bone diseases.
- 1 June 2006
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 4 (2) , 76-79
Bone quality: A perspective from the food and drug administration
Osteoporosis, a disease of compromised bone strength, is a leading cause of fracture, morbidity, and mortality. The past 10 years have resulted in the development of new pharmacologic therapies for the treatment of this disease. Most of these agents have been approved for the treatment of osteoporosis based on placebo-controlled fracture trials. However, recent ethical concerns regarding placebo-controlled trials threaten to derail the development of new, possibly better, treatment options. Novel noninvasive imaging technologies may offer greater insight into the pathophysiology and biomechanics of osteoporosis and fracture. Because of these advances, many hope to find a new biomarker that will predict fracture risk better than the current bone density measurements and that ultimately will replace fracture as the primary endpoint for osteoporosis drug registration trials. This paper discusses the perspective of a Food and Drug Administration reviewer regarding the role of surrogate markers as they relate to the quest for new, safe and efficacious treatments for osteoporosis.
- 1 June 2006
- Published by Springer Nature in Current Osteoporosis Reports
- Vol. 4 (2) , 76-79
Bone quality: A perspective from the food and drug administration
Osteoporosis, a disease of compromised bone strength, is a leading cause of fracture, morbidity, and mortality. The past 10 years have resulted in the development of new pharmacologic therapies for the treatment of this disease. Most of these agents have been approved for the treatment of osteoporosis based on placebo-controlled fracture trials. However, recent ethical concerns regarding placebo-controlled trials threaten to derail the development of new, possibly better, treatment options. Novel noninvasive imaging technologies may offer greater insight into the pathophysiology and biomechanics of osteoporosis and fracture. Because of these advances, many hope to find a new biomarker that will predict fracture risk better than the current bone density measurements and that ultimately will replace fracture as the primary endpoint for osteoporosis drug registration trials. This paper discusses the perspective of a Food and Drug Administration reviewer regarding the role of surrogate markers as they relate to the quest for new, safe and efficacious treatments for osteoporosis.